LDL cholesterol

Overview

Low-density lipoprotein cholesterol (LDL-C), often referred to as “LDL cholesterol,” is a major circulating cholesterol fraction and a central biomarker in cardiovascular medicine. It is widely used to assess atherosclerotic cardiovascular disease risk, and elevated LDL-C is considered a causal and modifiable risk factor for myocardial infarction and other ischemic events. In clinical practice, LDL-C is a primary treatment target in dyslipidemia, with goal attainment used to guide lipid-lowering therapy in patients with diabetes, pre-diabetes, normoglycaemia, familial hypercholesterolemia, and established cardiovascular disease.

Biologically, LDL particles transport cholesterol in the bloodstream, and excess LDL-C contributes to cholesterol deposition in arterial walls. This makes LDL-C a key endpoint in studies of statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, inclisiran, bempedoic acid, antisense therapies, and emerging genome-editing or peptide-based approaches. LDL-C is also frequently interpreted alongside apolipoprotein B, non-HDL cholesterol, triglycerides, remnant cholesterol, and inflammatory markers such as hs-CRP, because these measures together better characterize residual atherosclerotic risk.

Recent Publications Summary

Recent research on low-density lipoprotein cholesterol (LDL-C) management reveals persistent challenges in achieving therapeutic targets across diverse clinical populations. Multiple studies documented significant treatment gaps between guideline recommendations and real-world practice, with substantial variation based on socioeconomic factors, ethnicity, and sex 42270564Jun42331567Jun. In post-acute myocardial infarction populations, many patients failed to simultaneously achieve LDL-C and high-sensitivity C-reactive protein dual targets, particularly in Southeast Asian cohorts 42047130Apr. The prospective SANTORINI study examined LDL-C goal attainment through one-year follow-up stratified by diabetes status 42373176Jun, while pharmacist-led secondary prevention pathways emerged as strategies to reduce variation and improve LDL-C goal attainment among post-acute coronary syndrome patients 42331567Jun.

Pharmacological approaches for LDL-C reduction have expanded significantly with the adoption of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The VESALIUS-CV trial demonstrated that evolocumab, a PCSK9 inhibitor, effectively reduced LDL-C in patients with diabetes without known significant atherosclerosis, expanding the population considered for intensive lipid-lowering therapy 41903215Mar. High-intensity statin therapy showed associations with improved cardiovascular outcomes following percutaneous coronary intervention in patients with chronic coronary syndrome 41905939Mar, while proteomic analyses revealed distinct plasma protein profiles between heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia patients treated with PCSK9 inhibitors 41906435Mar. Cost-effectiveness analyses compared apolipoprotein B, non-high-density lipoprotein cholesterol, and LDL-C treatment targets for primary prevention lipid-lowering therapy 41949879Apr.

LDL-C associations with clinical outcomes extend beyond traditional cardiovascular endpoints. Higher LDL-C levels conferred greater risk for ST-segment elevation myocardial infarction compared to non-ST-segment elevation myocardial infarction in statin-treated patients with ischemic heart disease, suggesting differential effects by acute coronary syndrome subtype 41372774Dec. In community-dwelling adults over 50 years, discordance between apolipoprotein B and LDL-C correlated with cognitive function, potentially mediated by cerebral large and small-vessel disease 42396799Jul. Among type 2 diabetes patients, discordant high remnant cholesterol with elevated LDL-C increased risk for metabolic dysfunction-associated steatotic liver disease 42303421Jun. Integration of LDL-C with genomic polygenic risk scores and inflammatory biomarkers enhanced prediction of coronary artery disease risk 41848465Mar.

Research in specialized populations with genetic or acquired dyslipidemia has provided insights into extreme phenotypes and immunological associations. The Canadian Homozygous Familial Hypercholesterolemia Registry characterized treatment patterns and clinical outcomes in this rare disorder, marked by extremely elevated LDL-C and premature cardiovascular disease 42229223Jun. In HIV-infected individuals on antiretroviral therapy, the association between gut barrier integrity biomarkers and LDL-C appeared dependent on immune reconstitution, with regenerating islet-derived protein 3 alpha showing a strong positive correlation with LDL-C only in patients with CD4 counts below 350 cells/μL 42601778Aug. Dietary interventions, including Chardonnay grape marc and seed extract supplementation, were evaluated for effects on lipid parameters in adults with mild dyslipidemia 41894982Mar.

What Changes, What Holds

1. LDL-C goal attainment varies systematically by sex, ethnicity, and socioeconomic position
NEW DIRECTION Socioeconomic status, ethnicity, and sex drive meaningful differences in LDL-C goal achievement 42270564Jun42331567Jun, with treatment gaps between guideline recommendations and real-world practice. The Overview establishes LDL-C targets as a clinical standard across diverse populations but addresses only the biological rationale, not the healthcare equity dimensions that shape whether targets are actually met.

2. PCSK9 inhibitors reduce LDL-C in asymptomatic individuals with diabetes, expanding the case for preventive intensive therapy
REINFORCES Evolocumab effectively lowered LDL-C in patients with diabetes but without established atherosclerotic disease 41903215Mar, extending the case for preventive therapy. High-intensity statin therapy similarly showed cardiovascular benefit after coronary intervention 41905939Mar. These findings confirm what the Overview states—that PCSK9 inhibitors and statins are effective LDL-lowering agents—and expand the populations where these approaches apply without challenging the underlying rationale.

3. Apolipoprotein B and LDL-C discordance associates with cognitive outcomes and metabolic liver disease
NEW DIRECTION Discordant apoB and LDL-C patterns correlated with cognitive decline in older adults 42396799Jul, and high remnant cholesterol with elevated LDL-C increased metabolic dysfunction-associated steatotic liver disease risk 42303421Jun. The Overview notes that apoB and LDL-C are interpreted together but focuses only on cardiovascular applications. These findings extend LDL-related metabolism into organ systems—brain and liver—that the baseline does not cover.

4. LDL-C in HIV-positive individuals depends on immune reconstitution, and homozygous familial hypercholesterolemia represents an extreme phenotype requiring specialized management
NEW DIRECTION Gut barrier integrity biomarkers correlated with LDL-C only at lower immune reconstitution states (CD4 <350 cells/μL) in HIV-positive individuals on antiretroviral therapy 42601778Aug, and homozygous familial hypercholesterolemia presented with extremely elevated LDL-C and premature cardiovascular disease in the Canadian registry 42229223Jun. The Overview includes familial hypercholesterolemia as a treatment population but does not address the rare homozygous form, immune-dependent mechanisms, or LDL-C in HIV infection. These specialized populations reveal mechanistic complexity absent from the baseline.

Overview update candidates: treatment disparities by sex; ethnicity; and socioeconomic factors; LDL-C associations with cognitive and metabolic liver disease outcomes.